CD86 and Thrombocytopenia: In the case of 177Lu-DOTATATE, treatment of mice with 30-40 MBq (1500-2000 MBq/kg for 20 g mice, single dose) caused increased infiltration of CD86+ APC and FasL-expressing NK cells 93, yet the clinical use of 7.4 GBq (92.5 MBq/kg for 80 kg patients, 4 doses every 8 weeks) may cause neutropenia, thrombocytopenia, and lymphocytopenia (1%, 2%, and 9% of patients in the 177Lu-DOTATATE group, respectively) 123.